other · Healthcare · Biotechnology
MLYS
27.52+0.81 +3.03%Past year
Loading chart…
Loading financials…
Company snapshot
- Ticker
- MLYS
- Exchange
- NMS
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $2.39B
- Employees
- 76
- Currency
- USD
- Website
- https://mineralystx.com
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1,…
Latest coverage
No coverage yet — articles appear here automatically as press releases are published.
Related other stocks
Quotes & data
Follow Mineralys Therapeutics, Inc. (MLYS) across major market-data sources.